^
    Back
    Association details:
    Biomarker:FGFR2 fusion
    Cancer:Glioma
    Drug:Truseltiq (infigratinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Cholangiocarcinoma)
    New
    Excerpt:
    TRUSELTIQ is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

    Excerpt:
    ...Written documentation of local or central laboratory determination of amplification or translocation to FGFR1-TACC1, FGFR3-TACC-3 fusion and/or activating mutation in FGFR1, FGFR2,or FGFR3 3....
    Trial ID:
    NCT01975701
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    AACR 2019
    Title:

    Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors

    Excerpt:
    Infigratinib has also demonstrated efficacy in FGFR fusion+ PDX models of cholangiocarcinoma, breast cancer, liver cancer, gastric cancer and glioma.